Recent studies suggest that the risk of relapse in patients with schizophrenia is
approximately 3.5% per month. Predictors of more frequent relapses include poor …

Objective: The primary objective of this review is to evaluate the strategies used to improve
patient compliance with antipsychotic medication in the treatment of schizophrenia. Data …

We evaluated the efficacy of paliperidone extended-release (ER), an investigational
psychotropic agent, in delaying symptom recurrence in adult patients with schizophrenia …

Context Antipsychotic drugs are limited in their ability to improve the overall outcome of
schizophrenia. Adding psychosocial treatment may produce greater improvement in …

People with schizophrenia commonly lack insight, that is, they are unaware of their illness
and the consequences thereof. One of the most important consequences of lack of insight is …

Patients with schizophrenia are more likely than the general population to develop diabetes,
which contributes to a high risk of cardiovascular complications; individuals with …

Previous studies have suggested that a delay in initiating clozapine is one of the predictors
of outcomes in treatment-resistant schizophrenia (TRS). However, whether there is a critical …

Atypical antipsychotics (AAP) have been widely used for the management of patients with
schizophrenia and other psychotic disorders since they were introduced during the past …

Objective To study rates of relapse in remitted patients with first episode psychosis who
either continued or discontinued antipsychotic drugs after at least one year of maintenance …

Objective: To examine the impact of medication nonadherence on treatment outcome in
schizophrenia and potential risk factors for nonadherence. Method: A post hoc analysis of a …